Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292244 | 0.90 | HDAC8 (0.42) | POLBHDAC8NR1D1TACR1KMT2A | |
| SCHEMBL8067784 | 0.89 | CYP3A4 (0.44) | CYP1A2POLBCYP3A4CYP2C19HDAC8 | |
| SCHEMBL8064390 | 0.88 | HDAC8 (0.42) | HDAC8NR1D1TACR1KMT2A | |
| SCHEMBL8059551 | 0.88 | CYP1A2 (0.45) | CYP1A2POLBCYP3A4CYP2C19HDAC8 | |
| SCHEMBL4446450 | 0.86 | POLB (0.42) | CYP1A2POLBCYP3A4CYP2C19HDAC8 | |
| SCHEMBL4446456 | 0.86 | POLB (0.42) | CYP1A2POLBCYP3A4CYP2C19HDAC8 | |
| SCHEMBL5155194 | 0.85 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19KMT2A | |
| SCHEMBL6543115 | 0.85 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19KMT2A | |
| SCHEMBL13663630 | 0.83 | HDAC8 (0.39) | CYP1A2POLBCYP3A4CYP2C19HDAC8 | |
| SCHEMBL4305832 | 0.83 | S1PR5 (0.41) | NR1D1KMT2AHCRTR1HCRTR2ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| WO-2009026197-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | CYP1A2 974/4885POLB 690/4885CYP3A4 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.